Please login to the form below

Not currently logged in
Email:
Password:

ImmuNext

This page shows the latest ImmuNext news and features for those working in and with pharma, biotech and healthcare.

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

Last year, Lilly announced a $650m partnership with US biotech ImmuNext in the autoimmune disease area, which came just a few months after it launched a $620m partnership with Aduro Biotech

Latest news

  • Lilly and ImmuNext deal focused on autoimmune diseases Lilly and ImmuNext deal focused on autoimmune diseases

    In return, ImmuNext will grant Lilly a worldwide licence to develop and commercialise the novel immunometabolism target. ... In addition, Lilly and ImmuNext will establish a three year research collaboration to support the target's development.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch December 2016 Deal Watch December 2016

    453. ImmuNext (US). Roche (Switzerland). Licence. Rights to develop and commercialise therapeutic products that agonise the VISTA (negative checkpoint regulator) signalling pathway. ... ImmuNext. Roche. $400m. Not disclosed. Products that agonise the

  • Pharma deals during September 2012 Pharma deals during September 2012

    Lebanese company Immunext is developing novel therapeutics that modulate the immune system to treat cancer, and has announced a deal with Janssen Biotech. ... Nanocyclix technology platform for kinase inhibitors. 168. ImmuNext / Janssen Biotech. Licence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...